We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
The investor discussions surrounding Oxford Biomedica Plc (OXB) have centered on the company's recent developments and the overarching sentiment regarding its strategic position within the biopharmaceutical sector. A significant highlight from these conversations is the ongoing speculation around potential bids from larger players, likely aimed at bolstering their manufacturing capabilities. A contributor pointed out the interesting dynamics at the AGM, suggesting that there was a "feeling of potential vulnerability to an opportunistic bid," emphasizing that OXB's small-cap status may render it susceptible to acquisition attempts by mega-cap firms. The discussions reflect a broader concern among investors about OXB's share price performance and its positioning amid competitive pressures within the cell and gene therapy contract development and manufacturing organization (CDMO) space.
Financially, investors noted that OXB has projected sales of approximately £180 million for the upcoming year, which may signal a robust recovery plan after challenging periods. Several quotes echoed investor sentiment on this topic, with one user stating, "a record revenue year" could substantially enhance the company's valuation. Others provided mixed predictions for share price targets, with estimates ranging from £5.50 to as high as £10 over the next year, reflecting differing levels of optimism about OXB's ability to leverage its capabilities under current market conditions. Overall, the sentiment appears cautious yet hopeful, with a significant focus on upcoming strategic decisions and events, such as potential partnerships or acquisitions that could reshape the company’s trajectory.
Show more
Oxford Biomedica Plc (OXB) announced in a recent update that as of November 30, 2024, its issued share capital consists of 105,938,933 ordinary shares, with no shares held in treasury. This figure is important for shareholders as it serves as the denominator for calculating their obligations under the FCA's Disclosure Guidance and Transparency Rules regarding notifications of interest or changes in their interest in the company.
This announcement signals OXB's ongoing compliance with regulatory requirements as a public company while also providing shareholders with key information necessary for their governance and investment decisions. The company continues to focus on expanding its capabilities in the cell and gene therapy sectors, aiming to leverage its infrastructure for growth in the competitive market landscape.
Show more
Gareth |
A little over 400k shares traded so far today with the price all-over the place. |
Very possible Gareth, but world politics aside I think the coincidental Morgan Stanley Capital International quarterly review today is more significant for OXB shareholders short term. |
Look out for a bounce for OXB at 14.30pm GMT when NYSE opens. OXB usually pick up at this time. |
135k shares in the first 30 mins? Election bounce or someone who understands the MSCI criteria? |
Don't mention the election Phil. I mentioned it once, but I think I got away with it. |
So I think the MSCI result is tomorrow, or at least around 10pm tomorrow. Also with the US election (not necessarily conclusive results) - it should be interesting I guess. |
There were quite a lot of shares traded today (c230k) after a very slow start this morning. |
Chart looks good to me as a novice. Could be fireworks tonight? |
The Eurovision side of this always makes me smile. Anyway, back to OXB. |
Good to see a valued partner progressing Marcus, but just to clarify BEAM-201 is the CAR-T we partner them with. |
John Evans |
Oh dear ..this is how religious wars start. |
I would have thought Psalm 22 was more appropriate here. |
Even though I walk through the valley of the shadow of death, I fear no evil, for You are with me; Your rod and Your staff, they comfort me. |
Mainly heathens on the BBs Gareth. You may have to explain that. |
23rd Psalm, a Psalm of David? |
Many have made points in the past here about the number of shares firmly held these days and the decreasing fraction available to churn with the usual changes in supply and demand. I'm sure those aren't quite the correct terms, but as the likes of Blackrock (perhaps a bad example) appear holding 5% or more then what happens when news or some other event creates a sudden demand? |
All the buzz words there ‘operational gearing’,̵ |
I'm going to go into OXB OCD again here SJ, but the following may be of interest:- |
Columbia Threadneedle Management Limited is wholly owned by Columbia Threadneedle Holdings Limited, which is wholly owned by Columbia Threadneedle Group (Management) Limited, which is wholly owned by Columbia Threadneedle Group (Holdings) Limited, which is wholly owned by Columbia Threadneedle AM (Holdings) Plc, which is wholly owned by Columbia Threadneedle (Europe) Limited, which is wholly owned by Columbia Threadneedle Investments UK International Limited, which is wholly owned by Ameriprise Financial, Inc.which which which |
Well,i'll take it as reassuring without going too deeply into the rather opaque world of holding declarations.There can be an unsatisfactory delay between time of dealing and notification of a share holding and i would guess that this share purchase was the reason why the shares shot from 390 to around 440 in short order the week before last.It could be the large buyer which Dominic C understood was in the wings a fortnight back. |
Type | Ordinary Share |
Share ISIN | GB00BDFBVT43 |
Sector | Medicinal Chems,botanicl Pds |
Bid Price | 425.00 |
Offer Price | 427.00 |
Open | 430.00 |
Shares Traded | 258,355 |
Last Trade | 16:35:13 |
Low - High | 411.50 - 430.50 |
Turnover | 89.54M |
Profit | -184.16M |
EPS - Basic | -1.7479 |
PE Ratio | -2.43 |
Market Cap | 453.05M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions